Dual CDK4/6–PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma

Osteosarcoma (OS) in pediatric, adolescent, and young adult (AYA) patients is an aggressive bone cancer with limited treatment options. Dysregulation of the CDK4/6–cyclin D axis and the PI3K/mTOR pathway contributes to OS pathogenesis, providing a biological rationale for co-targeting these signalin...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Farinaz Barghi, M. Reza Saadatzadeh, Erika A. Dobrota, Harlan E. Shannon, Barbara J. Bailey, Courtney Young, Rada Malko, Ryli Justice, Niknam Riyahi, Christopher Davis, Khadijeh Bijangi-Vishehsaraei, Keiko Kreklau, Lauren K. Stevens, Jenna Koenig, Shirzat Sulayman, Sheng Liu, Jun Wan, Melissa A. Trowbridge, Kathy Coy, Felicia M. Kennedy, Anthony L. Sinn, Marissa Just, Kyle W. Jackson, George Sandusky, L. Daniel Wurtz, Christopher D. Collier, Dana Mitchell, Emily E. Seiden, Edward M. Greenfield, Emma Doud, Amber Mosley, Steven P. Angus, Michael J. Ferguson, Pankita H. Pandya, Karen E. Pollok
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-02-01
Serie:	Neoplasia: An International Journal for Oncology Research
Soggetti:	Osteosarcoma CDK4/6 PI3K/mTOR Senescence Autophagy Preclinical models
Accesso online:	http://www.sciencedirect.com/science/article/pii/S1476558625001459
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!